Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study-Reference-Cited by-同舟云学术

Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study

Published:2021-05-06 Issue:7 Volume:28 Page:765-773
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int. J. Urol.

Author:

Iguchi Taro¹^ORCID,Kimura Go²,Fukasawa Satoshi³,Suzuki Hiroyoshi⁴,Uemura Hiroji⁵,Nishimura Kazuo⁶,Matsumoto Hiroaki⁷^ORCID,Yokomizo Akira⁸,Armstrong Andrew J⁹,Rosbrook Brad¹⁰,Sugg Jennifer¹¹,Baron Benoit¹²,Chen Lucy¹¹,Kunieda Futoshi¹¹,Stenzl Arnulf¹³

Affiliation:

1. Osaka City University Graduate School of Medicine OsakaJapan

2. Nippon Medical School TokyoJapan

3. Chiba Cancer Center ChibaJapan

4. Toho University Sakura Medical Center ChibaJapan

5. Yokohama City University Medical Center YokohamaJapan

6. Osaka International Cancer Institute OsakaJapan

7. Graduate School of Medicine Yamaguchi University Hospital YamaguchiJapan

8. Harasanshin Hospital Fukuoka Japan

9. Duke Cancer Institute Center for Prostate and Urologic Cancers Durham North CarolinaUSA

10. Pfizer Inc. San Diego CaliforniaUSA

11. Astellas Pharma Inc. Northbrook Illinois USA

12. Astellas Pharma Inc. Leiden The Netherlands

13. Eberhard Karls University of Tübingen Tübingen Germany

Funder

Astellas Pharma

Pfizer

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.14568

Reference25 articles.

1. Center for Cancer Control and Information Services. Cancer Statistics in Japan – 2018. 2019. [Cited 29 Mar 2021.] Available from URL:https://ganjoho.jp/data/reg_stat/statistics/brochure/2018/cancer_statistics_2018.pdf

2. Epidemiology of prostate cancer in Asian countries

3. Combined androgen blockade for prostate cancer: Review of efficacy, safety and cost-effectiveness

4. MottetN CornfordP van denBerghRCNet al.EAU guidelines: prostate cancer. [Cited 3 Jul 2020.] Available from URL:https://uroweb.org/guideline/prostate‐cancer/#1

5. National Comprehensive Cancer Network.NCCN guidelines version 2.2020 prostate cancer. [Cited 28 Jun 2020.] Available from URL:https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide;International Journal of Clinical Oncology;2024-08-17

2. Cardiovascular risks of Asian patients on androgen-receptor-targeted agents for prostate cancer: a systematic review and meta-analysis;Prostate International;2024-08

3. Changes in the trends of initial treatment for newly diagnosed prostate cancer in Japan: a nationwide multi-institutional study;Japanese Journal of Clinical Oncology;2024-06-17

4. Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study;European Urology Oncology;2024-06

5. Prognostic outcomes in Japanese patients with metastatic castration‐sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor;International Journal of Urology;2024-05-19